NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims against Myriad Genetics, Inc. (NASDAQ:MYGN). Our investigation concerns whether Myriad has violated the federal securities laws and/or engaged in other unlawful business practices.
On March 12, 2018, Myriad announced that the Company had recently received a Subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The Subpoena requested that the Company produce documents relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.
Following this news, shares of Myriad fell $4.01 per share, or 12.1%, to close at $29.01 on March 13, 2018.
If you purchased or otherwise acquired Myriad shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Myriad Genetics, Inc., please go to http://www.bespc.com/MYGN. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.